|
1
|
Hutchinson L and Kirk R: High drug
attrition rates - where are we going wrong? Nat Rev Clin Oncol.
8:189–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cukierman E, Pankov R, Stevens DR and
Yamada KM: Taking cell-matrix adhesions to the third dimension.
Science. 294:1708–1712. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Erkan M, Hausmann S, Michalski CW,
Fingerle AA, Dobritz M, Kleeff J and Friess H: The role of stroma
in pancreatic cancer: Diagnostic and therapeutic implications. Nat
Rev Gastroenterol Hepatol. 9:454–467. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Neesse A, Michl P, Frese KK, Feig C, Cook
N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, et al:
Stromal biology and therapy in pancreatic cancer. Gut. 60:861–868.
2011. View Article : Google Scholar
|
|
5
|
Partensky C: Toward a better understanding
of pancreatic ductal adenocarcinoma: Glimmers of hope? Pancreas.
42:729–739. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oettle H: Progress in the knowledge and
treatment of advanced pancreatic cancer: From benchside to bedside.
Cancer Treat Rev. 40:1039–1047. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Coleman SJ, Watt J, Arumugam P, Solaini L,
Carapuca E, Ghallab M, Grose RP and Kocher HM: Pancreatic cancer
organotypics: High throughput, preclinical models for
pharmacological agent evaluation. World J Gastroenterol.
20:8471–8481. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hwang CI, Boj SF, Clevers H and Tuveson
DA: Preclinical models of pancreatic ductal adenocarcinoma. J
Pathol. 238:197–204. 2016. View Article : Google Scholar
|
|
10
|
Cardone RA, Greco MR, Zeeberg K,
Zaccagnino A, Saccomano M, Bellizzi A, Bruns P, Menga M, Pilarsky
C, Schwab A, et al: A novel NHE1-centered signaling cassette drives
epidermal growth factor receptor-dependent pancreatic tumor
metastasis and is a target for combination therapy. Neoplasia.
17:155–166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kimlin L, Kassis J and Virador V: 3D in
vitro tissue models and their potential for drug screening. Expert
Opin Drug Discov. 8:1455–1466. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alves F, Contag S, Missbach M, Kaspareit
J, Nebendahl K, Borchers U, Heidrich B, Streich R and Hiddemann W:
An orthotopic model of ductal adenocarcinoma of the pancreas in
severe combined immunodeficient mice representing all steps of the
metastatic cascade. Pancreas. 23:227–235. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hebner C, Weaver VM and Debnath J:
Modeling morphogenesis and oncogenesis in three-dimensional breast
epithelial cultures. Annu Rev Pathol. 3:313–339. 2008. View Article : Google Scholar
|
|
15
|
Yamada KM and Cukierman E: Modeling tissue
morphogenesis and cancer in 3D. Cell. 130:601–610. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Collisson EA, Sadanandam A, Olson P, Gibb
WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, et al:
Subtypes of pancreatic ductal adenocarcinoma and their differing
responses to therapy. Nat Med. 17:500–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sipos B, Möser S, Kalthoff H, Török V,
Löhr M and Klöppel G: A comprehensive characterization of
pancreatic ductal carcinoma cell lines: Towards the establishment
of an in vitro research platform. Virchows Arch. 442:444–452.
2003.PubMed/NCBI
|
|
18
|
Edmondson R, Broglie JJ, Adcock AF and
Yang L: Three-dimensional cell culture systems and their
applications in drug discovery and cell-based biosensors. Assay
Drug Dev Technol. 12:207–218. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Navas C, Hernández-Porras I, Schuhmacher
AJ, Sibilia M, Guerra C and Barbacid M: EGF receptor signaling is
essential for k-ras oncogene-driven pancreatic ductal
adenocarcinoma. Cancer Cell. 22:318–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Froeling FE, Mirza TA, Feakins RM, Seedhar
A, Elia G, Hart IR and Kocher HM: Organotypic culture model of
pancreatic cancer demonstrates that stromal cells modulate
E-cadherin, beta-catenin, and Ezrin expression in tumor cells. Am J
Pathol. 175:636–648. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Antelmi E, Cardone RA, Greco MR, Rubino R,
Di Sole F, Martino NA, Casavola V, Carcangiu M, Moro L and Reshkin
SJ: β1 integrin binding phosphorylates ezrin at T567 to activate a
lipid raft signalsome driving invadopodia activity and invasion.
PLoS One. 8:e751132013. View Article : Google Scholar
|
|
22
|
Canel M, Serrels A, Frame MC and Brunton
VG: E-cadherin-integrin crosstalk in cancer invasion and
metastasis. J Cell Sci. 126:393–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Clucas J and Valderrama F: ERM proteins in
cancer progression. J Cell Sci. 127:267–275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wendt MK, Taylor MA, Schiemann BJ and
Schiemann WP: Down-regulation of epithelial cadherin is required to
initiate metastatic outgrowth of breast cancer. Mol Biol Cell.
22:2423–2435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sawada K, Mitra AK, Radjabi AR, Bhaskar V,
Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A,
Kenny HA, et al: Loss of E-cadherin promotes ovarian cancer
metastasis via alpha 5-integrin, which is a therapeutic target.
Cancer Res. 68:2329–2339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qin R, Smyrk TC, Reed NR, Schmidt RL,
Schnelldorfer T, Chari ST, Petersen GM and Tang AH: Combining
clinicopathological predictors and molecular biomarkers in the
oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in
resectable pancreatic cancer. Br J Cancer. 112:514–522. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kremer KN, Dudakovic A, Hess AD, Smith BD,
Karp JE, Kaufmann SH, Westendorf JJ, van Wijnen AJ and Hedin KE:
Histone deacetylase inhibitors target the leukemic microenvironment
by enhancing a Nherf1-protein phosphatase 1α-TAZ signaling pathway
in osteoblasts. J Biol Chem. 290:29478–29492. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Malfettone A, Silvestris N, Paradiso A,
Mattioli E, Simone G and Mangia A: Overexpression of nuclear NHERF1
in advanced colorectal cancer: Association with hypoxic
microenvironment and tumor invasive phenotype. Exp Mol Pathol.
92:296–303. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Troncoso M, Cuello Carrión FD, Guiñazu E,
Fanelli MA, Montt-Guevara M, Cabrini RL, Carón RW and Kreimann EL:
Expression of NHERF1 in colonic tumors induced by
1,2-dimethylhydrazine in rats is independent of plasma ovarian
steroids. Horm Cancer. 2:214–223. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cardone RA, Bellizzi A, Busco G, Weinman
EJ, Dell'Aquila ME, Casavola V, Azzariti A, Mangia A, Paradiso A
and Reshkin SJ: The NHERF1 PDZ2 domain regulates
PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor
cells. Mol Biol Cell. 18:1768–1780. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang B, Means CK, Yang Y, Mamonova T,
Bisello A, Altschuler DL, Scott JD and Friedman PA: Ezrin-anchored
protein kinase A coordinates phosphorylation-dependent disassembly
of a NHERF1 ternary complex to regulate hormone-sensitive phosphate
transport. J Biol Chem. 287:24148–24163. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cardone RA, Greco MR, Capulli M, Weinman
EJ, Busco G, Bellizzi A, Casavola V, Antelmi E, Ambruosi B,
Dell'Aquila ME, et al: NHERF1 acts as a molecular switch to program
metastatic behavior and organotropism via its PDZ domains. Mol Biol
Cell. 23:2028–2040. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee JM, Mhawech-Fauceglia P, Lee N,
Parsanian LC, Lin YG, Gayther SA and Lawrenson K: A
three-dimensional microenvironment alters protein expression and
chemosensitivity of epithelial ovarian cancer cells in vitro. Lab
Invest. 93:528–542. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Godugu C, Patel AR, Desai U, Andey T, Sams
A and Singh M: AlgiMatrix™ based 3D cell culture system as an
in-vitro tumor model for anticancer studies. PLoS One.
8:e537082013. View Article : Google Scholar
|
|
35
|
Baker BM and Chen CS: Deconstructing the
third dimension: How 3D culture microenvironments alter cellular
cues. J Cell Sci. 125:3015–3024. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: Mechanisms,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
|
|
37
|
Longati P, Jia X, Eimer J, Wagman A, Witt
MR, Rehnmark S, Verbeke C, Toftgård R, Löhr M and Heuchel RL: 3D
pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant
phenotype offering a better model for drug testing. BMC Cancer.
13:952013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Denayer S, Stöhr T and Van Roy M: Animal
models in translational medicine: Validation and prediction. New
Horiz Transl Med. 2:5–11. 2014. View Article : Google Scholar
|
|
39
|
Greek R and Menache A: Systematic reviews
of animal models: Methodology versus epistemology. Int J Med Sci.
10:206–221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Härmä V, Schukov HP, Happonen A, Ahonen I,
Virtanen J, Siitari H, Åkerfelt M, Lötjönen J and Nees M:
Quantification of dynamic morphological drug responses in 3D
organotypic cell cultures by automated image analysis. PLoS One.
9:e964262014. View Article : Google Scholar : PubMed/NCBI
|
